These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

166 related articles for article (PubMed ID: 35701863)

  • 21. Trichomonas Vaginalis Infections Among Youth in Detention in the Southeastern United States.
    Oshin E; Eissa MA; Benjamins LJ; Barratt MS; Beyda RM
    J Pediatr Adolesc Gynecol; 2022 Jun; 35(3):368-370. PubMed ID: 34610441
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Offering routine trichomonas vaginalis testing to patients presenting for abortion at an urban hospital-based clinic.
    Cheeks ML; Schwartz R; Oleson EC; Cohen S; Drey EA; Seidman D
    Contraception; 2021 Jun; 103(6):423-425. PubMed ID: 33539801
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Prevalence of Trichomoniasis by PCR in Women Attending Health Screening in Korea.
    Kim SR; Kim JH; Gu NY; Kim YS; Hong YC; Ryu JS
    Korean J Parasitol; 2016 Apr; 54(2):187-90. PubMed ID: 27180577
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Epidemiology, Natural History, Diagnosis, and Treatment of Trichomonas vaginalis in Men.
    Van Gerwen OT; Camino AF; Sharma J; Kissinger PJ; Muzny CA
    Clin Infect Dis; 2021 Sep; 73(6):1119-1124. PubMed ID: 34079999
    [TBL] [Abstract][Full Text] [Related]  

  • 25. British Association of Sexual Health and HIV national guideline on the management of sexually acquired reactive arthritis 2021.
    Carlin E; Marzo-Ortega H; Flew S
    Int J STD AIDS; 2021 Oct; 32(11):986-997. PubMed ID: 34014782
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Factors associated with Trichomonas vaginalis infection in reproductive-aged women attending cervical screening in southeast of Brazil.
    da Silva Pinto GV; Bolpet ADN; Martin LF; Moço NP; Ramos BRA; Silva MC; Duarte MTC; da Rocha Tristão A; da Silva MG; Marconi C
    Braz J Infect Dis; 2023; 27(4):102794. PubMed ID: 37500061
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Attitudes of women participating in a clinical trial on point-of-care testing and home testing for STIs.
    Chow K; Edi R; Gin G; Morris SR
    Int J STD AIDS; 2020 Dec; 31(14):1352-1358. PubMed ID: 32996866
    [No Abstract]   [Full Text] [Related]  

  • 28. Trichomoniasis: the "neglected" sexually transmitted disease.
    Meites E
    Infect Dis Clin North Am; 2013 Dec; 27(4):755-64. PubMed ID: 24275268
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Prevention or treatment: the benefits of Trichomonas vaginalis vaccine.
    Cudmore SL; Garber GE
    J Infect Public Health; 2010; 3(2):47-53. PubMed ID: 20701891
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Recent advances in the epidemiology, diagnosis, and management of
    Van Gerwen OT; Muzny CA
    F1000Res; 2019; 8():. PubMed ID: 31583080
    [No Abstract]   [Full Text] [Related]  

  • 31. Trichomonas vaginalis in Turkey--a review.
    Saygi G
    Wiad Parazytol; 2001; 47 Suppl 1():3-7. PubMed ID: 16897944
    [No Abstract]   [Full Text] [Related]  

  • 32. Large two-centre study into the prevalence of Mycoplasma genitalium and Trichomonas vaginalis in the Netherlands.
    de Jong AS; Rahamat-Langendoen JC; van Alphen P; Hilt N; van Herk C; Pont S; Melchers W; van de Bovenkamp J
    Int J STD AIDS; 2016 Sep; 27(10):856-60. PubMed ID: 26199286
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Prevalence and risk factors for
    Mabaso N; Naicker C; Nyirenda M; Abbai N
    Int J STD AIDS; 2020 Mar; 31(4):351-358. PubMed ID: 32075536
    [No Abstract]   [Full Text] [Related]  

  • 34. Trichomonas vaginalis prevalence, incidence, risk factors and antibiotic-resistance in an adolescent population.
    Krashin JW; Koumans EH; Bradshaw-Sydnor AC; Braxton JR; Evan Secor W; Sawyer MK; Markowitz LE
    Sex Transm Dis; 2010 Jul; 37(7):440-4. PubMed ID: 20351623
    [TBL] [Abstract][Full Text] [Related]  

  • 35. A cross-sectional analysis of
    Bochner AF; Baeten JM; Rustagi AS; Nakku-Joloba E; Lingappa JR; Mugo NR; Bukusi EA; Kapiga S; Delany-Moretlwe S; Celum C; Barnabas RV;
    Sex Transm Infect; 2017 Nov; 93(7):520-529. PubMed ID: 28377421
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Prevalent, treatable and significant: barriers to the control of Trichomonas vaginalis in women.
    Hillier SL
    Sex Transm Infect; 2013 Sep; 89(6):415. PubMed ID: 23956294
    [No Abstract]   [Full Text] [Related]  

  • 37. High prevalence of Chlamydia trachomatis, Neisseria gonorrhoeae and particularly Trichomonas vaginalis diagnosed using US FDA-approved Aptima molecular tests and evaluation of conventional routine diagnostic tests in Ternopil, Ukraine.
    Boiko I; Golparian D; Krynytska I; Unemo M
    APMIS; 2019 Sep; 127(9):627-634. PubMed ID: 31225920
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Trichomoniasis: challenges to appropriate management.
    Wendel KA; Workowski KA
    Clin Infect Dis; 2007 Apr; 44 Suppl 3():S123-9. PubMed ID: 17342665
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Identification of volatile biomarkers of Trichomonas vaginalis infection in vaginal discharge and urine.
    Rubio-Sánchez R; Ríos-Reina R; Ubeda C
    Appl Microbiol Biotechnol; 2023 May; 107(9):3057-3069. PubMed ID: 37000228
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Changing sexually transmitted infection screening protocol will result in improved case finding for trichomonas vaginalis among high-risk female populations.
    Roth AM; Williams JA; Ly R; Curd K; Brooks D; Arno J; Van Der Pol B
    Sex Transm Dis; 2011 May; 38(5):398-400. PubMed ID: 21217417
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.